by Raynovich Rod | Dec 10, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Tradeable Intermediate Bottom Today 12:36P… 12/15 GILD 102.8,IBB 331 Update at Close Update…Sunday 12/13/15…Grim Outlook…Risk Off The market sunk further Friday afternoon after 3p for a NASDAQ close at 4933 off 2.33% (up 4.17% YTD) for the...
by Raynovich Rod | Dec 2, 2015 | 2024 Rayno Tools and Diagnostics Portfolio
Dominant Trend is Precision Medicine and Molecular Medicine Lackluster revenue growth has tempered stock gains since Q3 earnings reports however the sector has always had good investment potential due to M&A and new products. Stocks are up from October lows. Our...
by Raynovich Rod | Nov 25, 2015 | Biopharmaceuticals
Slow But Steady Biotech Rally RNA Therapeutics-Duchenne Muscular Dystrophy (DMD) Despite some overhanging concerns about drug pricing and major setbacks from clinical trials like Clovis Oncology (CLVS) and BioMarin Pharmaceutical (BMRN) the sector looks like it wants...
by Raynovich Rod | Nov 5, 2015 | 2024 Rayno Tools and Diagnostics Portfolio
Looking for Value in a Slow Growth Market Life Science stocks took a big hit over the past summer and many have not fully recovered.The important metric to watch is sales growth because many of the smaller cap companies are still lagging in earnings growth so the PE...
by Raynovich Rod | Oct 30, 2015 | Biopharmaceuticals
Biotech Innovation Seeks Value Healthcare Costs Mount The Bio Investor Forum has become a go-to meeting for biotech investors and company executives. Although the presenting companies are early stage or smaller cap public companies the attendees are broadly...
by Raynovich Rod | Oct 27, 2015 | Biopharmaceuticals
10/29/15 Update Large Cap Biotechs Update Amgen (AMGN) Revenues Grow 14%, beats street. 2016 Revenues guided to ~$22B, flattish revenue growth with higher EPS $10.35-$10.75. 2015 PEG=1.80, P/S=5.94, Div. 1.94% Rayno Biopharmaceutical Portfolio Large Caps up 2.6% YTD,...
by Raynovich Rod | Oct 22, 2015 | Biopharmaceuticals
Summary for the Week of Oct 19:Markets Up on Central Banks Easing;Techs Lead the Way IBB up 0.62%- 316.3 bottomed on Wednesday. QQQ up 4.3%- 112.78 up big Thursday and Friday. XBI down o.58%- 65.67 in choppy trading. XLI up 4%- 54.66 steady climb from Monday. XLV...
by Raynovich Rod | Oct 19, 2015 | Biopharmaceuticals
October 21 Update 9:45a EDT NASDAQ up 0.4% IBB up 1.57% 1:45p EDT Biotech Thrashing Continues-High Fliers Hit Hardest Healthcare stocks remain under attack with the XLV down 1.5% and the IBB down 1.6%.Healthcare is the sector loser down 2% while the Industrials are...
by Raynovich Rod | Oct 13, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Life Science ETF's and Mutual Funds
10/15 After the Close… XBI Up 7.26%…Green Screen…MOmentum is back Biotech stocks soared today in a broad rally showing a good appetite especially for small and mid-cap stocks. This could be a counter-trend rally in a biotech bear market but there is...
by Raynovich Rod | Sep 29, 2015 | Biopharmaceuticals
Another Rally from FED minutes…except biotech 10/8/15 … BIOTECH-Another test near 2015 lows in early AM ; choppy downtrend but look for a bottoming process as market is turning up toward close: IBB at 306 down slightly after reversal XBI down 1.7% to 63.3...